Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dicks Sporting Goods Inc (DKS) vs Gilead Sciences, Inc. (GILD) Price & Performance

Dicks Sporting Goods IncTrade
Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

Dicks Sporting Goods Inc vs Gilead Sciences, Inc. — how do they compare? Dicks Sporting Goods Inc trades at $206.29 (market cap $19.16B), while Gilead Sciences, Inc. trades at $135 (market cap $164.99B). The key difference: Gilead Sciences, Inc. is far larger — about 8.6× Dicks Sporting Goods Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.47%). Which is the better fit depends on your goals.

DKSGILD
Market Cap
$19.16B$164.99B
Sector
Consumer CyclicalHealth
52-Week High
$239.17$155.80
52-Week Low
$187.78$110.56
Enterprise Value
$25.95B$188.06B
Dividend Yield
2.34%2.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dicks Sporting Goods Inc

DICK'S Sporting Goods (DKS) trades at $208.84, up 5.15% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows neutral technical signals with support at $201 and resistance at $213. Fundamentally, the company maintains solid profitability with 20.9% ROE and 4.71% net margin, though cash flow trends show modest net outflows. Recent news highlights analyst upgrades and the upcoming Q2 earnings call on August 25th.

The investment outlook remains positive with 59% analyst buy ratings and a $263.22 consensus target representing 26% upside. Key risks include potential fiduciary duty investigations and competitive pressures in sporting goods retail. The company's consistent earnings beats and expanding women's sports investments provide catalysts, though investors should monitor cash flow sustainability and market volatility.

Gilead Sciences, Inc.

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dicks Sporting Goods Inc

Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.

Read more on DKS

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD